Thursday , June 20 2019
Home / zimbabwe / Treatment of obesity and liver disease can be achieved

Treatment of obesity and liver disease can be achieved

Treatment of obesity and liver disease may be within range

Hebrew University of Jerusalem Professor Amiram Goldblum. Credit: Hebrew University of Jerusalem

Amiram Goldblum and his team at the Hebrew University of Jerusalem Institute for Drug Research discovered 27 new molecules. All of these molecules activate a special protein called PPAR-delta and have the potential to treat fatty liver disease, obesity, diabetic nephrotoxicity and healing wounds.

Reports of these findings were released today in 2008 Scientific reports, Nature magazine and became a new award-winning algorithm developed by the Goldblum team. This algorithm went through 1.56 million molecules and chose 27 with a strong therapeutic potential, as biologists at the Novartis Genomic Institute (GNF) in San Diego.

To date, these new molecules undergo pharmaceutical evaluation to treat two major health conditions. The first is Fatty Liver Disease, also known as NASH (Non-Alcoholic SteatoHeptatis). This disease currently has no cure and is the main cause of liver cancer in the Western world. The other is obesity. Activation of PPAR-delta has the potential to increase physical endurance and adorn the waistline so that muscle cells burn more fat. Future assessments may include testing of treatment for better wound healing and prevention of kidney toxicity in diabetics.

Professor Goldblum is cautiously optimistic about these findings. "With such a large group of highly active molecules, there is a high probability of finding cure for several common illnesses, but we should wait until all attempts are complete before we get too much hope," he said.

There is still considerable pharmaceutical interest in new Goldblum molecules. Integra Holdings, a biotechnology company at the Hebrew University, found that 21 out of 27 had the potential to achieve pharmaceutical success, especially as a possible cure for oily liver disease. Israel's Heller Institute for Medical Research also tests the physical endurance properties of PPAR in mice. Goldblum predicts that in a few years we will probably see some of these molecules in the preparation of clinical trials for humans.

The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver diseases

More information:
Benny Da & apos; adoosh et al. The discovery of highly selective and diverse PPAR-delta agonists using machine-based learning based on ligand and structural modeling, Scientific reports (2019). DOI: 10.1038 / s41598-019-38508-8

Hebrew University of Jerusalem

Treatment of obesity and fatty liver disease may be reached (2019, 31 January)
Uploaded 31 January 2019

This document is copyrighted. Apart from any fair dealing for private studies or research, no
Part can be reproduced without written permission. Content is provided for information purposes only.

Source link